Results 1 to 10 of about 89 (87)
Escherichia coli O157 was first identified as a human pathogen in 1982. One of several Shiga toxin-producing serotypes known to cause human illness, the organism probably evolved through horizontal acquisition of genes for Shiga toxins and other virulence factors. E.
Mead, Paul S., Griffin, Patricia M.
openaire +3 more sources
Screening for Escherichia coli O157:H7 in Illinois [PDF]
OBJECTIVE: To determine the incidence of infection with Escherichia coli O157:H7 in a tertiary referral center in Chicago, where a similar study had been performed in 1984, to evaluate cases of disease reported to the Illinois Department of Public Health (IDPH) in 1993, and to determine laboratory practices used to detect this infection throughout the ...
Fischer, Staci A. +7 more
openaire +2 more sources
An Escherichia coli O157:H7 Outbreak? [PDF]
© 2000 by the Infectious Diseases Society of America. All rights reserved.
Bettelheim, K., Goldwater, P.
openaire +2 more sources
Cryo‐electron microscopy structures reveal two distinct neutralization mechanisms of fully human monoclonal antibodies targeting the Shiga toxin 1a B subunit. RDS059 occludes the Gb3 receptor‐binding site, whereas RDS045 engages a lateral quaternary epitope to disrupt holotoxin assembly.
Jianting Ke +10 more
wiley +1 more source
Survival of Escherichia coli O157:H7 on Cattle Hides [PDF]
ABSTRACT The objective of this study was to determine the time period that Escherichia coli O157:H7 survives on the hides of cattle. Extensive research has been conducted and is ongoing to identify and develop novel preharvest intervention strategies to reduce the presence of E. coli
Arthur, Terrance M. +5 more
openaire +2 more sources
Bridging the translational gap in clinical nanomedicine: From rational design to clinical reality
Nanotechnology offers a multi‐faceted approach to modern healthcare, encompassing high‐sensitivity diagnostic imaging, innovative vaccine delivery, and targeted therapeutics. This review explores how these nanomedicine applications address critical challenges in cancer recurrence and the treatment of neurologic and respiratory diseases to combat rising
Ahmed H. Ghonaim +9 more
wiley +1 more source
Experimental Escherichia coli O157:H7 carriage in calves [PDF]
Nine weaned calves (6 to 8 weeks of age) were given 10(10) CFU of a five-strain mixture of enterohemorrhagic Escherichia coli O157:H7 by oral-gastric intubation. After an initial brief period of pyrexia in three calves and transient mild diarrhea in five calves, calves were clinically normal throughout the 13- to 27-day study. The population of E. coli
C A, Brown +3 more
openaire +2 more sources
Antimicrobial Peptides and Peptidomimetics in Foods – A Synthetic Foray
This Review discusses AMPs in foods and their syntheses. It espouses facile methods to make them accessible and suggests their utility in the mitigation and eradication of the burgeoning maladies of antimicrobial and multidrug resistance (AMR and MDR).
Josephat U. Izunobi +2 more
wiley +1 more source
Chlorine Inactivation of Escherichia coli O157:H7
We analyzed isolates of Escherichia coli O157:H7 (which has recently caused waterborne outbreaks) and wild-type E. coli to determine their sensitivity to chlorination. Both pathogenic and nonpathogenic strains were significantly reduced within 1 minute of exposure to free chlorine.
Eugene W. Rice +2 more
openaire +3 more sources
Pulsed light technology uses short high‐intensity broad‐spectrum flashes (200–1100 nm) to inactivate microbes via DNA damage. It preserves food quality, extends shelf life, and works on liquids, meats, and produce, often combined with other hurdles for enhanced efficacy.
Abdul Mueez Ahmad +4 more
wiley +1 more source

